Vote Scores

Home / Companies / TAKEDA PHARMACEUTICAL CO LTD / 24 Jun 2026

Meeting · year to 30 June 202626 filers reporting

TAKEDA PHARMACEUTICAL CO LTD: meeting of 24 Jun 2026

Votes reported on Form N-PX, item by item

26 Form N-PX filers reported votes at the TAKEDA PHARMACEUTICAL CO LTD meeting of 24 Jun 2026. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

12 nominees; 96.7% of reported votes for; 5 filers withheld from or voted against at least one nominee.

296 vote records from 21 filers. 0 of the 20 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

95.2% for0.0% against4.8% other0.0% against management21 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

5 vote records from 3 filers. 0 of the 3 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management3 filers99.6% for0.0% against0.4% other0.0% against management50,737 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

7 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management6 filers100.0% for0.0% against0.0% against management380,527 reported shares
4

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

24 vote records from 20 filers. 0 of the 20 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management20 filers100.0% for0.0% against0.0% against management11,896,980 reported shares, counted once per item in this group
5

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

29 vote records from 18 filers. 0 of the 17 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

94.4% for0.0% against5.6% other0.0% against management18 filers99.4% for0.6% against0.0% against management11,986,769 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors
VanguardFor
BlackRock and iSharesFor
FidelityFor
DimensionalFor
American CenturyFor
Goldman SachsFor
First TrustFor
Columbia ThreadneedleFor
Capital Group and American FundsFor
VanEckFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the TAKEDA PHARMACEUTICAL CO LTD meeting?

26 Form N-PX filers reported votes at the meeting of 24 Jun 2026. On say-on-pay, 0 of 3 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by TAKEDA PHARMACEUTICAL CO LTD on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for TAKEDA PHARMACEUTICAL CO LTD

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing TAKEDA PHARMACEUTICAL CO LTD with a meeting date within three days of 24 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.